Wedbush lowered the firm’s price target on Omega Therapeutics to $12 from $19 and keeps an Outperform rating on the shares. Omega reported Q3 results, and expects to share updated clinical data from the MYCHELANGELO dose escalation study of OTX-2002 in 1H24, the analyst tells investors in a research note. The firm also looks forward to the initiation of monotherapy and combination expansion cohorts, anticipated in mid-2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OMGA:
- Omega Therapeutics reports Q3 EPS (40c), consensus (53c)
- Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
- Omega presents new preclinical data on pre-transcriptional control of genes
- Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller
- Omega Therapeutics presents new preclinical data on OTX-2101
